【重磅新品】TL1A-DR3 (TR-FRET) 试剂盒：完善TL1A药物工具矩阵

TL1A-DR3通路在炎症性肠病（IBD）中通过激活免疫细胞释放炎症因子导致肠道炎症加重，其表达水平与IBD病情相关，开发可抑制TL1A-DR3信号通路的抑制剂药物已经成为IBD治疗策略。为充分满足生物药开发企业在IBD药物开发过程中快速发现和验证抑制TL1A-DR3相互作用候选分子的需求，ACROBiosystems重磅推出TL1A-DR3 (TR-FRET) 抑制检测试剂盒，具有高灵敏度、高特异性、操作简便、重复性高等产品特点，为您的TL1A-DR3抑制剂筛选供有力支持！

>>>点击图片，了解TL1A抑制剂筛选试剂盒产品及订购信息

时间分辨荧光共振能量转移（Time-Resolved Fluorescence Resonance Energy Transfer，TR-FRET）是一种用于检测生物分子相互作用的高灵敏度、高通量筛选技术。它结合了荧光共振能量转移（FRET）和时间分辨荧光（TRF）的优点，能有效降低背景荧光信号干扰，从而获得更加准确的检测结果。

TR-FRET工作原理基于两个荧光分子的能量转移

TR-FRET的工作原理基于两个荧光分子的能量转移。当供体荧光分子被激发后，它的能量会在与受体分子相距极近时（通常小于10纳米）通过FRET机制传递给受体分子，受体随之发出荧光。TR-FRET的核心在于使用长寿命的供体荧光分子，例如Eu3+、Tb3+等镧系元素的螯合物。与传统的FRET技术不同，TR-FRET通过延迟荧光信号的检测时间来过滤掉背景信号中的短寿命荧光，从而提升了信号的检测灵敏度和准确度。TL1A-DR3 (TR-FRET) 抑制检测试剂盒的具体优势包括：

从药物开发市场来看，2023上半年来针对TL1A靶点自免研究及开发取得显著进展。随着当前非肿瘤领域热度不断上升，跨国药企们对IBD领域的关注度也越来越高：2023年至今该IBD领域已达成至少6项大额重磅交易，参与方包括默沙东、罗氏、赛诺菲、艾伯维、礼来等药企，表明其在收购这条路上越走越宽，这也一定程度反映出TL1A靶点高市场热度以及MNC药企的发展策略。

为满足TL1A生物药开发需求，ACROBiosystems百普赛斯从【为更好的生物医药】出发并强化产品布局，开发了可满足从分子层面到细胞层面应用的一系列高品质TL1A生物药开发工具，包括：

>>>点击列表查看TL1A天然三聚体重组蛋白产品

>>>点击列表查看DR3重组蛋白产品

>>>点击列表查看TL1A报告株，过表达株产品

>>>点击列表查看TL1A:DR3 (ELISA) 抑制剂筛选试剂盒产品

>>>点击列表查看TL1A-DR3 (TR-FRET) 抑制检测试剂盒产品

ACROBiosystems百普赛斯对所有产品均进行逐批质检，对纯度、结合活性等性能进行了验证，并将研发人员的实验操作和参数形成相应的Protocol免费提供，帮助您节省研发周期。

Inhibition of Europium-chelate labeled human TL1A: FA labeled human DR3 binding by Human Anti-TL1A Neutralizing Antibody
Premix serial dilutions of Human Anti-TL1A Neutralizing Antibody (1:2 serial dilution, from 10 μg/mL to 0.01953125 μg/mL (66.6667-0.1302 nM)) and Human TL1A Protein Europium-chelate (Cat. No. FRT-02) and incubate at room temperature (20℃-25℃) for 0.5 hours. Then add FA Labeled Human DR3 Protein and incubate at room temperature (20℃-25℃) for 0.5 hours. Detection was performed with IC50 of 2.816nM. The assay was performed according to the above-described Datasheet (QC tested).

• TL1A蛋白：高生物活性经ELISA验证

Immobilized Cynomolgus/Rhesus macaque TL1A / TNFSF15, His Tag (Cat. No. TLA-C5241) at 5 μg/mL (100 μL/well) can bind Human DcR3, Fc Tag (Cat. No. TNB-H5255) with a linear range of 0.2-10 ng/mL (QC tested).

点击申请Protocol

• TL1A蛋白：高纯度经SDS-PAGE，SEC-MALS验证

纯度 (Purity) ：经SDS－PAGE验证大于90%，经SEC-MALS验证大于90%

The purity of Human DLL3, His Tag (Cat. No. TLA-M5243) is greater than 90% verified by SDS-PAGE and more than 90% verified by SEC-MALS.

• TL1A功能株：蛋白激活活性经FOLD验证

Response to human TL1A protein (FOLD).

This reporter cell （Cat. No. SCJUR-STF178）was incubated with serial dilutions of human  TL1A protein (Cat. No. TLA-H5243). The max induction fold was approximately 40.12.

点击申请Protocol

• DR3蛋白：高生物活性经SPR验证

Biotinylated Human TL1A Protein, His,Avitag (Cat. No. TLA-H52Q1) immobilized on SA Chip can bind Human DR3 Protein, His Tag (Cat. No. TN5-H52H3) with an affinity constant of 2.59 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

点击申请Protocol

• TL1A抑制剂筛选试剂盒：中和抗体结合验证

Serial dilutions of Human Anti-TL1A Neutralizing antibody (Cat. No. EP168) (1:1 serial dilution, from 20μg/mL to 0.3125μg/mL) was added into Human DR3: Biotinylated Human TL1A (Cat. No. EP168) 　binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).

For each experiment, a standard curve needs to be set for each micro-plate, and the specific OD value may vary depending on different laboratories, testers, or equipments. The example data is for reference only.